Research Topics
Species | Melissa A GellerSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignanciesMelissa A Geller
Division of Gynecologic Oncology, University of Minnesota, Department of Obstetrics, Gynecology and Women s Health, Minneapolis, MN 55455, USA
Eur J Obstet Gynecol Reprod Biol 143:93-7. 2009..To evaluate the feasibility and morbidity of using saline filled tissue expanders (TE) to displace the small bowel during radiation therapy in patients with gynecologic malignancies...- Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancerMelissa A Geller
Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
Int J Gynecol Cancer 20:918-25. 2010..Our objective was to investigate chemotherapy-induced modulation of MCP-1 in ovarian cancer by investigating macrophage infiltration, tumor vascularity, and MCP-1 expression after chemotherapy exposure... - A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancerMelissa A Geller
Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
Gynecol Oncol 121:112-7. 2011..To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer... - Learning about ovarian cancer at the time of diagnosis: video versus usual careMelissa A Geller
Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
Gynecol Oncol 119:370-5. 2010..We evaluated the effects of an educational video on patients' distress, cancer knowledge, coping skills and attitudes regarding learning about cancer at the time of ovarian cancer diagnosis... - A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinomaMelissa A Geller
Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
Gynecol Oncol 118:19-23. 2010..We sought to evaluate the outcomes and feasibility associated with delivering sequential chemotherapy and radiation in advanced stage endometrial cancer... - Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancersMelissa A Geller
Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, MMC 395 420 Delaware St SE, Minneapolis, MN, 55455, USA
Cancer Immunol Immunother 59:1877-84. 2010..Secondary objectives included assessment of safety and immune system activation... 
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinomaLevi S Downs
Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
Cancer 112:331-9. 2008..Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide...- A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancerPeter A Argenta
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
Gynecol Oncol 113:205-9. 2009..Grade 1 toxicity included headache (1 patient) and bromidrosis (2 patients). Conclusions. Fulvestrant is well-tolerated and efficacious. Objective response rates are low, but disease stabilization was common... - Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trialLevi S Downs
Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
Gynecol Oncol 120:265-9. 2011.... - Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expressionMelissa A Geller
Department of Obstetrics and Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Gynecol Oncol 95:632-6. 2004..Expression of c-kit was common, especially in high-grade lesions and may represent a potential therapeutic target... - Multimodal therapy improves survival in patients with CNS metastasis from uterine cancer: a retrospective analysis and literature reviewJustin C Chura
Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Division of Gynecologic Oncology, 420 Delaware Street SE, MMC 395, Minneapolis, MN 55455, USA
Gynecol Oncol 107:79-85. 2007..Consequently, the optimal management strategy is not defined. We reviewed our institution's experience with brain metastasis from endometrial cancer along with the extant medical literature to develop management recommendations... 
Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarkerMelissa S DeRycke
Dept of Laboratory Medicine and Pathology, MMC 609, 420 Delaware St, SE, Minneapolis, MN 55455, USA
Am J Clin Pathol 134:835-45. 2010....- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancerMelissa A Geller
Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Cytotherapy 13:98-107. 2011..We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer... - Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancerPatricia L Judson
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, 420 Delaware Street Southeast, MMC 395, Minneapolis, MN 55455, USA
Gynecol Oncol 91:389-94. 2003.... - Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot studyPeter A Argenta
Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
Gynecol Oncol 129:81-5. 2013..We aimed to evaluate the feasibility and tolerability of hyperthermic intraperitoneal carboplatin (HIPEC-carboplatin) following secondary cytoreduction for recurrent, platinum-sensitive ovarian cancer... - Menopausal hormone therapy and risk of colorectal cancerJill R Johnson
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
Cancer Epidemiol Biomarkers Prev 18:196-203. 2009..55; 95% CI, 0.32-0.98) had the largest risk reduction. In this study, estrogen plus progestin use, especially sequential regimen use, was associated with the largest overall reduction of colorectal cancer risk... - A multi-institutional review of outcomes of endometrial stromal sarcomaCharles A Leath
Department of Obstetrics, Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA
Gynecol Oncol 105:630-4. 2007..To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively... - Effect of age and comorbidity on the treatment and survival of older patients with vulvar cancerRAHEL G GHEBRE
Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55417, USA
Gynecol Oncol 121:595-9. 2011..To determine the disease characteristics and comorbidities predictive of vulvar cancer specific mortality and five year overall survival among older women, ages 65 and above... - Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patientsJohn D Andersen
Department of Laboratory Medicine and Pathology, University of Minnesota, MMC 609, 420 Delaware St, SE Minneapolis, MN, USA
J Ovarian Res 3:21. 2010..We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry... - Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature reviewJustin C Chura
University of Minnesota, Department of Obstetrics, Gynecology, and Women s Health, 420 Delaware Street SE MMC 395, Minneapolis, MN 55455, USA
Gynecol Oncol 104:247-52. 2007..Studies have suggested that PET scans can differentiate between leiomyomas and leiomyosarcomas. Our experience, however, shows that PET scan-positive smooth muscle tumors are not necessarily malignant... - Gonadal dysgenesis and gynecologic cancerAmy L Jonson
Division of Gynecologic Oncology, University of Minnesota Department of Obstetrics, Gynecology, Women s Health, Minneapolis, Minnesota, USA
Obstet Gynecol 116:550-2. 2010..Gonadal dysgenesis encompasses a variety of sexual differentiation disorders. Within this population of patients, there is an increased risk of gonadal tumor formation...